Skip to main content
    D

    Dermata Therapeutics Inc (DRMA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.60
    -0.02 (-3.65%)

    Market Cap: $3.06M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    Dermata Therapeutics Inc (DRMA) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Dermata Therapeutics (DRMA) to earn -$2.17 per share in the fiscal year ending Dec 31, 2026, on revenue of $100000. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$1.43.

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 650.0%.

    Fiscal year ending Dec 31, 2026
    -$2.17
    EPS consensus, revenue $100000
    Fiscal year ending Dec 31, 2027
    -$1.43
    EPS consensus, revenue $750000
    Next report
    Mar 24, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$2.17-$2.17 to -$2.171$100000$100000 to $1000001
    Dec 31, 2027-$1.43-$1.43 to -$1.431$750000$750000 to $7500001

    Quarterly Estimates

    The EPS consensus rises from -$0.47 for the quarter ending Dec 31, 2026 to -$0.42 for the quarter ending Mar 31, 2027.

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.47N/A3$76500$73500 to $787503
    Mar 31, 2027-$0.42-$0.42 to -$0.421$100000$100000 to $1000001

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202710
    Quarter ending Mar 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.20.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$2.17-$2.21-$2.21-$2.21-$2.20N/A
    Fiscal year ending Dec 31, 2027-$1.43-$1.52-$1.52-$1.52-$1.49N/A

    Frequently Asked Questions About DRMA

    What is the DRMA stock forecast?

    Consensus analyst estimates put Dermata Therapeutics's EPS at -$2.17 for the fiscal year ending Dec 31, 2026, on revenue of $100000.

    What EPS do analysts expect from DRMA next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.17, with estimates from -$2.17 to -$2.17 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.43, with estimates from -$1.43 to -$1.43 from 1 analyst.

    What revenue do analysts expect from Dermata Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $100000, with estimates from $100000 to $100000. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $750000, with estimates from $750000 to $750000.

    How many analysts cover DRMA?

    1 analyst estimates EPS for Dermata Therapeutics for the fiscal year ending Dec 31, 2026.